To Study Generic Fluticasone Propionate Inhalation Aerosol for the Treatment of Bronchial Asthma

Authors
Category Primary study
Registry of Trialsclinicaltrials.gov
Year 2022
This is a randomized, assessor-blind, placebo controlled, multicenter, clinical endpoint bioequivalence study to compare the efficacy and safety of generic fluticasone propionate inhalation aerosol USP 44 mcg (Glenmark Pharmaceuticals Ltd) to Flovent HFA (fluticasone propionate inhalation aerosol) 44 mcg (GSK group of companies) in treatment of patients with bronchial asthma.
Epistemonikos ID: ad381399f73a6a05f419df30ff754cf696ca8eb6
First added on: May 13, 2024